Hancke K, Grubeck D, Hauser N, Kreienberg R, Weiss J M
Department of Obstetrics and Gynaecology, University of Ulm, Prittwitzstr. 43, 89075 Ulm, Germany.
Breast Cancer Res Treat. 2010 Jan;119(2):367-7. doi: 10.1007/s10549-009-0577-9.
Several adipocytokines, such as leptin or adiponectin, are associated with obesity and the risk for breast cancer. Adiopcyte fatty acid binding-protein(A-FABP) is another protein found in adipose tissue;therefore, we investigated the association of A-FABP with the occurrence and prognosis of breast cancer. In our study,200 women attending the University of Ulm for breast surgery between the years 2005 and 2007 were included;159 had histologically confirmed breast cancer; 41 had histologically confirmed benign lesions. Serum levels ofA-FABP, leptin, and adiponectin were measured, and their relationship to body-mass-index (BMI), breast cancer, and tumor characteristics were analyzed; logistic regression model was adjusted to age, BMI, menopausal status, use of Hormone Replacement Therapy (HRT), and family history of breast cancer. Serum A-FABP levels were found to be significantly higher in obese (BMI C 25) than in non-obese women (BMI B 24.9), 41.16 ng/ml and 24.95 ng/ml,respectively (P\0.0001). Independent of obesity, the serum A-FABP levels were significantly higher in breast cancer patients (34.65 ng/ml) than in healthy controls(24.47 ng/ml), P\0.0001; the odds ratio (1.038, P\0.05,95% confidence interval 1.001-1.72) showed a significant association of A-FABP with breast cancer risk. Serum leptin levels showed a strong correlation with BMI(rs = 0.78) and were significantly higher in breast cancer patients (20.87 ng/ml) than in controls (14.90 ng/ml),P\0.05. In contrast, adiponectin showed no significant association with breast cancer. Concerning tumor characteristics,A-FABP was positively connected with tumor size (T C 2 cm, P\0.05) and nodal-status (P\0.05).Our study reveals that high A-FABP serum levels are associated with obesity, breast cancer risk, and adverse tumor characteristics.
几种脂肪细胞因子,如瘦素或脂联素,与肥胖及患乳腺癌风险有关。脂肪细胞脂肪酸结合蛋白(A-FABP)是在脂肪组织中发现的另一种蛋白质;因此,我们研究了A-FABP与乳腺癌发生及预后的关系。在我们的研究中,纳入了200名于2005年至2007年间在乌尔姆大学接受乳房手术的女性;159例经组织学确诊为乳腺癌;41例经组织学确诊为良性病变。检测了血清中A-FABP、瘦素和脂联素水平,并分析了它们与体重指数(BMI)、乳腺癌及肿瘤特征的关系;逻辑回归模型根据年龄、BMI、绝经状态、激素替代疗法(HRT)的使用情况及乳腺癌家族史进行了校正。结果发现,肥胖(BMI≥25)女性的血清A-FABP水平显著高于非肥胖女性(BMI≤24.9),分别为41.16 ng/ml和24.95 ng/ml(P<0.0001)。与肥胖无关,乳腺癌患者的血清A-FABP水平(34.65 ng/ml)显著高于健康对照者(24.47 ng/ml),P<0.0001;优势比(1.038,P<0.05,95%置信区间1.001-1.72)表明A-FABP与乳腺癌风险存在显著关联。血清瘦素水平与BMI呈强相关(rs = 0.78),且乳腺癌患者(20.87 ng/ml)显著高于对照组(14.90 ng/ml),P<0.05。相比之下,脂联素与乳腺癌无显著关联。关于肿瘤特征,A-FABP与肿瘤大小(T≥2 cm,P<0.05)和淋巴结状态(P<0.05)呈正相关。我们的研究表明,血清A-FABP水平升高与肥胖、乳腺癌风险及不良肿瘤特征有关。